Unit

UNIT 10.4 Clinical and Neuroimaging Assessments for Research Studies (Including Drug Trials) in Multiple Sclerosis

  1. Michelle L. Apperson,
  2. Mark A. Agius

Published Online: 1 JAN 2011

DOI: 10.1002/0471142301.ns1004s54

Current Protocols in Neuroscience

Current Protocols in Neuroscience

How to Cite

Apperson, M. L. and Agius, M. A. 2011. Clinical and Neuroimaging Assessments for Research Studies (Including Drug Trials) in Multiple Sclerosis. Current Protocols in Neuroscience. 54:10.4:10.4.1–10.4.16.

Author Information

  1. Department of Neurology, University of California Davis and VA Northern California Health System (VANCHS), Sacramento, California

Publication History

  1. Published Online: 1 JAN 2011
  2. Published Print: JAN 2011

Abstract

Multiple sclerosis (MS) is an immune-mediated disorder causing inflammation and demyelination in the central nervous system. As the onset of multiple sclerosis is at a young age, it is one of the leading neurological causes of disability. Disease activity and disability can be measured by neurological assessments and by magnetic resonance imaging. The development of standardized assessments has been a very important step in clinical research in MS. Clinical research in MS has led to a better understanding of the disease itself and has resulted in exciting new therapies. The protocols provided in this unit are four basic clinical and neuroimaging assessments commonly used as outcome measures in clinical research studies of MS subjects. These step-by-step instructions may be used by researchers and neurologists in clinical practice to obtain objective measures of MS disease progression and response to treatments. Curr. Protoc. Neurosci. 54:10.4.1-10.4.16. © 2011 by John Wiley & Sons, Inc.

Keywords:

  • multiple sclerosis;
  • clinical trials;
  • EDSS;
  • MSFC;
  • MRI